Hindustan Times (Delhi)

IN WOMEN, FERTILITY AND ORGASM ARE NOT CONNECTED. IN MEN, THEY ARE INSEPARABL­E.

- *Name changed on request

WOMEN BEAR THE BURDEN OF CONTRACEPT­ION ALTHOUGH FEMALE STERILISAT­ION IS PRONE TO INFECTIONS AND WORSE. BUT MANY WOMEN OPT FOR IT BECAUSE THEY ARE WEARY OF FREQUENT PREGNANCIE­S.

itself (planning replaced welfare).

“After that, nobody was willing to touch this (vasectomy) with a barge pole,” says a public health expert working with the Ministry of Health and Family Welfare who spoke on the condition of anonymity. The problem with the vasectomy, Guha explains, is that it’s permanent. It blocks sperm forcing the body to produce antibodies that destroy the excessive build-up, which brings down the sperm count. The longer a vasectomy lasts, the lesser the chance of reversing its effects.

Guha and his students invented a molecule that took the form of a transparen­t , gooey liquid. When injected into the two tubes leading to the penis, it takes root like a spider web but firmer. The sperm isn’t blocked because it can pass through the gaps. But, in the process, the gel destroys vital membranes that enable the sperm to fertilise the egg. A second reversible injection, yet to be tested on humans, will dismantle the molecular web.

RISUG attracted interest from pharma companies but it waned — as a one-time, affordable procedure it offers low margins. And in countries like India, where the demand for family planning is huge, the biggest buyer is often the government. Both Pfizer and Bayer told HT male contracept­ives are not a priority currently. The last few attempts, including by Bayer in the early 2000s, made little headway.

Guha licensed the RISUG technology to a US-based non-profit, Parsemus Foundation, that is developing the drug for the non-Indian market. Executive director Linda Brent said in an email that the drug, renamed Vasalgel, has a new formulatio­n to suit regulatory standards in the US and Europe. It’s being tested on animals.

She believes money, not demand, is a challenge for male contracept­ives, which are usually funded by government­s or nonprofits. Parsemus’ surveys, she said, show that some men “wish to relieve their partners of the burden of birth control,” while many want a male contracept­ive so they “have direct control over whether they become fathers.”

So why has there been no male contracept­ive? Some of it is pure biology: it’s hard to block the millions of sperm that are produced every day. Any one of them can fertilise an egg. “It’s easy to mess around with ovulation,” says Ruma Satwik, a reproducti­ve medicine specialist at Delhi’s Gangaram Hospital. “Egg production is a very, very, very, delicate process.” Ten different hormones have to do their job just right to produce an egg. And they get just one chance every month. Stress, diet or any sort of hormonal imbalance can interrupt this: that’s what birth control pills and intrauteri­ne devices (IUDs) do.

Satwik’s most vivid memory of her stint running a primary health centre (PHC) in rural Maharashtr­a is meeting the District Health Officer, a short, dark, kindly man in cotton trousers and a shirt. The year was 2000. India’s population had crossed the one billion mark.

And the pressure was on: PHCs had to meet their “targets”, recorded in a ruled register, for IUDs, birth control pills, condoms and, most of all, female sterilisat­ion.

Every month, Satwik would assemble along with 50 other doctors from the district and answer the same question: Tum che kithi? (How many?) “If she (a woman) was still menstruati­ng, she was a candidate,” Satwik says. The question was largely about female sterilisat­ion, which has remained the go-to form of family planning for successive Indian government­s.

A vasectomy is safer because it’s a minor surgery with no side effects. When women undergo sterilisat­ion, the incision is deeper and the chances of an infection, higher. Oral contracept­ives like the birth control pill come with side effects; and inserts such as IUDs are not ideal in large, poor countries where women are more susceptibl­e to vaginal infections and doctors aren’t necessaril­y qualified to perform the procedure.

So why not push vasectomie­s more? The firm but unfounded fear that male contracept­ion will somehow hamper masculinit­y and the pleasure of sexual release. “Fertility and orgasm are delinked in women,” Satwik says. “In men they are insepara- ble.” Many men worry that contracept­ives that impede their fertility will also interfere with their orgasm.

“Sex power kum ho jaayega (will decrease).” That, health worker Nurjamal Haque says, concerns men when they are asked to consider a vasectomy. Haque is a community advocate in rural Assam’s Barapeta district: he travels across tiny river islands educating people about the merits of family planning. And he’s relentless. He spent nearly three years persuading a single community elder to allow his 32-year-old wife to undergo sterilisat­ion. Until he agreed, Haque couldn’t convince any of the others in the community either.

“Slowly, slowly, change comes but it takes a lot of hard work,” Haque says in a phone interview. Eight years ago, he couldn’t broach the subject in many of these parts; he and his colleagues were routinely harassed for trying. But now staunch community elders have turned “motivators” and some women are coming to the clinic asking for condoms for their husbands. “One day, the way women come on their own, men will also come,” says Haque. “That is my belief.”

The annual reports of advocacy groups such as the Population Foundation, which work with the government on family planning and other health issues, is filled with uplifting stories of persistent efforts that paid off in rural communitie­s; of women who chose their own birth control; of husbands who were eventually convinced; of couples who negotiated and picked what’s best for them.

But there’s also data: of malnourish­ed, anaemic women; of frequent pregnancie­s; of widening sex ratios. And there are other stories too. “The mothers-in-law are the gatekeeper­s,” says *Mehak Sharma, a quantitati­ve researcher who has spent hundreds of hours speaking or at least trying to speak to women in remote villages in Uttar Pradesh, Bihar, Rajasthan and Maharashtr­a. The government’s Accred- ited Social Health Activist (ASHA), Sharma says, has to get past the mother-inlaw. Then, she’ll often find herself talking under the watchful eye of a sister-in-law.

Sharma’s job is to decode the behaviour behind decisions about family planning, among other things. What is the preferred method and why. In poor communitie­s, she says, she often finds that women don’t think they have a choice. “The first kid is supposed to come like that,” says Sharma, snapping her fingers. “I’m married, I have to have kids — what’s there to think or talk about? You don’t make decisions for yourself. It’s intimidati­ng.”

The decision, Sharma says, usually comes from the doctor because there is no dialogue between husband and wife. Even educated men are not necessaril­y involved in the decision. She recalls a woman in Mumbai telling her she got her IUD removed because it made her husband physically uncomforta­ble. Sharma couldn’t understand what she meant and the woman couldn’t explain either.

The question that concerns doctors and advocates is this: if men are so reluctant to use condoms or even discuss contracept­ion, will they consent to being injected with a drug that would disarm their sperm?

None of this perturbs Guha. That, he explains, is not his job. “Research and developmen­t — that is life,” he says. Once RISUG gets approved, he says, he wants to start working on a version of it for women: the same gel would enter the fallopian tubes and disintegra­te the egg.

“There is enough work for me,” he says, chuckling. ” Is he excited that the drug is nearly past clinical trials? Or dishearten­ed that it took this long? After a brief pause, he offers a nugget of wisdom that he inherited from his father: “One should never be happy or sad about anything.”

 ?? GETTY IMAGES AND SAUMYA KHANDELWAL ?? (L) A research assistant prepares a syringe at a laboratory for a male contracept­ive at IIT Kharagpur. (Above) Doctors at a hospital in Delhi inject 29yearold Fauji with the contracept­ive as part of an ongoing clinical trial.
GETTY IMAGES AND SAUMYA KHANDELWAL (L) A research assistant prepares a syringe at a laboratory for a male contracept­ive at IIT Kharagpur. (Above) Doctors at a hospital in Delhi inject 29yearold Fauji with the contracept­ive as part of an ongoing clinical trial.
 ??  ??
 ??  ??

Newspapers in English

Newspapers from India